Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['cilta cel', 'cartitude-4', '3 car,(-23 care)', 'mmsm', 'cartitude', ' emd ']
#mmsm #asco23 cartitude-4
early crossing of km in the first 3 months. the numbers of progression events or deaths that were reported during trial weeks 0 to 8 were higher in the cilta cel group than in standard-care. notice there was 5% higher amount of emd in cilta cel 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities